☆ 4.3 Review

Oxaliplatin-based chemotherapy in the management of colorectal cancer

EXPERT REVIEW OF ANTICANCER THERAPY (2008)

期刊

EXPERT REVIEW OF ANTICANCER THERAPY

卷 8, 期 8, 页码 1223-1236

出版社

TAYLOR & FRANCIS LTD

DOI: 10.1586/14737140.8.8.1223

关键词

adjuvant treatment; advanced disease; bevacizumab; cetuximab; colorectal cancer; mechanism of action; neurotoxicity; oxaliplatin

类别

Oncology

向作者/读者索取更多资源

Protocol

Reagent

摘要

Oxaliplatin is the only third-generation platinum derivative compound that has found a place in the routine treatment of colorectal cancer (CRC). The appearance of oxaliplatin, as well as irinotecan, in the CRC treatment armamentarium has offered new standards for adjuvant treatment and greater hopes in metastatic disease. Moreover, the combination of oxaliplatin-based chemotherapy with new targeted drugs has improved response rates and survival of these patients. Despite these new approaches, the prognosis of CRC remains poor and a better understanding of the molecular pathways is needed to optimize the use of these new approaches. In this review, the authors examine the development of oxaliplatin as well as the main trials that have positioned oxaliplatin as a key drug in the treatment of CRC.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Pharmacology & Pharmacy

Oxaliplatin-induced peripheral neurotoxicity in colorectal cancer patients: mechanisms, pharmacokinetics and strategies

Fang Cheng, Ruoqi Zhang, Chen Sun, Qian Ran, Cuihan Zhang, Changhong Shen, Ziqing Yao, Miao Wang, Lin Song, Cheng Peng

Summary: Oxaliplatin-based chemotherapy is a standard treatment for colorectal cancer but can cause severe peripheral neurotoxicity. This article explores the mechanisms, therapeutic strategies, and pharmacokinetics of different methods of oxaliplatin administration to counteract this toxicity. Strategies include combination with chemoprotectants, timing modulation of infusion, dose reduction, reintroduction of oxaliplatin, and topical administration.

FRONTIERS IN PHARMACOLOGY (2023)

添加到收藏夹

Review Oncology

Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer

Christina Teng, Jordan Cohen, Sam Egger, Prunella L. Blinman, Janette L. Vardy

Summary: Chemotherapy-induced peripheral neuropathy (CIPN) caused by oxaliplatin is a common long-term side effect for colorectal cancer survivors, with prevalence decreasing over time. The study identified a variety of tools used in different studies to measure CIPN, highlighting the need for a standardized assessment.

SUPPORTIVE CARE IN CANCER (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy

Changjing Cai, Qingqing Luo, Yihan Liu, Yinghui Peng, Xiangyang Zhang, Zhaohui Jiang, Ziyang Feng, Yaru Qi, Yan Gao, Yongting Liu, Ping Liu, Yihong Chen, Cao Guo, Hong Shen, Shan Zeng, Ying Han

Summary: This study conducted a comprehensive analysis of treatment regimens for left-sided RAS wild-type metastatic colorectal cancer (mCRC) and found that the double-drug regimen plus cetuximab/panitumumab was more effective and safer than the double-drug and triple-drug regimens with bevacizumab.

FRONTIERS IN PHARMACOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

Gerald W. Prager, Julien Taieb, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Elena Elez, Felipe M. Cruz, Lucjan Wyrwicz, Daniil Stroyakovskiy, Zsuzsanna Papai, Pierre-Guillaume Poureau, Gabor Liposits, Chiara Cremolini, Igor Bondarenko, Dominik P. Modest, Karim A. Benhadji, Nadia Amellal, Catherine Leger, Loick Vidot, Josep Tabernero

Summary: In this study, researchers found that treatment with trifluridine-tipiracil plus bevacizumab could prolong overall survival in patients with metastatic colorectal cancer compared to trifluridine-tipiracil alone.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Oncology

Cetuximab versus bevacizumab following prior FOLFOXIRI and bevacizumab in postmenopausal women with advanced KRAS and BRAF wild-type colorectal cancer: a retrospective study

Chunlong Huang, Xiaoyuan Gu, Xianshang Zeng, Baomin Chen, Weiguang Yu, Meiji Chen

Summary: The study demonstrated that CET showed superior survival benefit compared to BEV, with fewer tolerable adverse events.

BMC CANCER (2021)

添加到收藏夹

Article Oncology

Clinical Validation of a Machine-learning-derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer

Jim P. Abraham, Daniel Magee, Chiara Cremolini, Carlotta Antoniotti, David D. Halbert, Joanne Xiu, Phillip Stafford, Donald A. Berry, Matthew J. Oberley, Anthony F. Shields, John L. Marshall, Mohamed E. Salem, Alfredo Falcone, Axel Grothey, Michael J. Hall, Alan P. Venook, Heinz-Josef Lenz, Anthony Helmstetter, W. Michael Korn, David B. Spetzler

Summary: The study identified a molecular signature, FOLFOXai, that can predict the efficacy of oxaliplatin-based chemotherapy combined with bevacizumab in patients with metastatic colorectal cancer, with predictive value for treatment adjustment and survival outcomes, and was validated in TRIBE2 samples.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial

Marla Lipsyc-Sharf, Fang-Shu Ou, Matthew B. Yurgelun, Douglas A. Rubinson, Deborah Schrag, Shaker R. Dakhil, Philip J. Stella, Douglas J. Weckstein, Donald B. Wender, Meredith Faggen, Tyler J. Zemla, Erica N. Heying, Samantha R. Schuetz, Stephanie Noble, Jeffrey A. Meyerhardt, Tanios Bekaii-Saab, Charles S. Fuchs, Kimmie Ng

Summary: The study investigated the efficacy of combining bevacizumab with irinotecan and cetuximab in patients with irinotecan-refractory metastatic colorectal cancer. Although there was no significant difference in progression-free survival between the two treatment groups, there was a statistically significant improvement in overall survival favoring the group that received bevacizumab in addition to irinotecan and cetuximab. Further investigation on this combination therapy is warranted.

ONCOLOGIST (2022)

添加到收藏夹

Editorial Material Medicine, General & Internal

Combination Therapy, Including Bevacizumab, for Advanced Colorectal Cancer

Oladapo O. Yeku, Dan L. Longo

Summary: This editorial discusses the scientific basis of a clinical trial conducted by Prager and colleagues, which tested the efficacy of trifluridine-tipiracil and bevacizumab in treating patients with refractory metastatic colorectal cancer.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Oncology

First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group

Marinde J. G. Bond, Karen Bolhuis, Olaf J. L. Loosveld, Jan Willem B. de Groot, Helga Droogendijk, Helgi H. Helgason, Mathijs P. Hendriks, Joost M. Klaase, Geert Kazemier, Mike S. L. Liem, Arjen M. Rijken, Cornelis Verhoef, Johannes H. W. de Wilt, Koert P. Jong, Michael F. Gerhards, Martinus J. van Amerongen, Marc R. W. Engelbrecht, Krijn P. van Lienden, I. Quintus Molenaar, Bart de Valk, Brigitte C. M. Haberkorn, Emile D. Kerver, Frans Erdkamp, Robbert J. van Alphen, Danielle Mathijssen-van Stein, Aysun Komurcu, Marta Lopez-Yurda, Rutger-Jan Swijnenburg, Cornelis J. A. Punt, Dutch Colorectal Canc Study Grp

Summary: This study compared the efficacy of different induction regimens in patients with initially unresectable colorectal cancer liver metastases. The results showed that FOLFOXIRI-bevacizumab was the preferred treatment for patients with right-sided primary tumor or RAS/BRAFV600E mutation, while the addition of panitumumab to FOLFOX or FOLFIRI in patients with left-sided and RAS/BRAFV600E wild-type tumor showed no clinical benefit but more toxicity.

LANCET ONCOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer A Randomized Clinical Trial

Antonio Avallone, Maria C. Piccirillo, Guglielmo Nasti, Gerardo Rosati, Chiara Carlomagno, Elena Di Gennaro, Carmela Romano, Fabiana Tatangelo, Vincenza Granata, Antonino Cassata, Lucrezia Silvestro, Alfonso De Stefano, Luigi Aloj, Valeria Vicario, Anna Nappi, Alessandra Leone, Domenico Bilancia, Laura Arenare, Antonella Petrillo, Secondo Lastoria, Ciro Gallo, Gerardo Botti, Paolo Delrio, Francesco Izzo, Franco Perrone, Alfredo Budillon

Summary: In this study, sequential administration of bevacizumab with chemotherapy did not improve the objective response rate as expected, but did show an advantage in overall survival, reduced adverse effects, and improved quality of life, suggesting potential for further exploration of antiangiogenic combination treatments.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Oncology

Comparative Effectiveness of Bevacizumab versus Cetuximab in Metastatic Colorectal Cancer Patients without Primary Tumor Resection

Yi-Chia Su, Chih-Chien Wu, Chien-Chou Su, Meng-Che Hsieh, Ching-Lan Cheng, Yea-Huei Kao Yang

Summary: This study assessed the effectiveness of bevacizumab and cetuximab therapies in patients with metastatic colorectal cancer who did not undergo primary tumor resection. The results showed that cetuximab-based therapy had significantly better survival and conversion surgery rates compared to bevacizumab-based therapy in these patients.

CANCERS (2022)

添加到收藏夹

Article Oncology

Treatment strategies to resectable metachronous colorectal liver metastases after adjuvant oxaliplatin-based chemotherapy for primary colorectal cancer

Camille Julio, Stephane Benoist, Marc-Antoine Allard, Francis Navarro, Patrick Pessaux, Antonio Sa Cunha, Antoine Brouquet

Summary: The background outcome of patients with resectable metachronous colorectal liver metastases after adjuvant oxaliplatin-based chemotherapy for colorectal cancer is not well defined, and the value of preoperative chemotherapy is controversial.

JOURNAL OF SURGICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Effectiveness of Hyperthermia as Monotherapy and Adjuvant Therapy Approaches Against an In Vitro Model of Colorectal Carcinoma

Georgios Petrakis, Theodora Mantso, Michail Koukourakis, Mihalis Panayiotidis, Sotiris Botaitis

Summary: In this study, an optimized hyperthermic protocol was developed against an in vitro model of human colon carcinoma as a promising monotherapy and/or adjuvant therapy approach. The protocol showed the potential to potentiate chemotherapeutic and targeted drug-induced cytotoxicity against colorectal carcinoma to a variable degree.

ANTICANCER RESEARCH (2022)

添加到收藏夹

Article Oncology

Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen

Hiroaki Tanioka, Ken Shimada, Akihito Tsuji, Mitsugu Kochi, Ho Min Kim, Takao Takahashi, Tadamichi Denda, Akinori Takagane, Takanori Watanabe, Masahito Kotaka, Masato Nakamura, Y. U. Sunakawa, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii

Summary: The SIRB regimen showed promising efficacy and safety as a second-line treatment option for patients with oxaliplatin and cetuximab-refractory KRAS wild-type mCRC.

ANTICANCER RESEARCH (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

Elena Elez, Javier Ros, Jose Fernandez, Guillermo Villacampa, Ana Belen Moreno-Cardenas, Carlota Arenillas, Kinga Bernatowicz, Raquel Comas, Shanshan Li, David Philip Kodack, Roberta Fasani, Ariadna Garcia, Javier Gonzalo-Ruiz, Alejandro Piris-Gimenez, Paolo Nuciforo, Grainne Kerr, Rossana Intini, Aldo Montagna, Marco Maria Germani, Giovanni Randon, Ana Vivancos, Ron Smits, Diana Graus, Raquel Perez-Lopez, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio, Rodrigo Dienstmann, Josep Tabernero, Rodrigo A. Toledo

Summary: In colorectal cancer patients, inactivating mutations in the RNF43 gene are associated with patients' response rates and survival outcomes to anti-BRAF/EGFR therapy. This suggests that the status of the RNF43 gene may serve as a predictive biomarker for patients' clinical outcomes.

NATURE MEDICINE (2022)

添加到收藏夹

Article Oncology

Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond

Maria Alsina, Josep Tabernero, Marc Diez

Summary: Gastric cancer is a global healthcare problem with multiple symptoms and fragility in patients. Multidisciplinary teams are required for palliative care and nutritional support. Sequential treatment is the best approach, and a third-line treatment can improve survival and quality of life.

CANCERS (2022)

添加到收藏夹

Article Oncology

GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells

Chiara Bellio, Marta Emperador, Pol Castellano, Albert Gris-Oliver, Francesc Canals, Alex Sanchez-Pla, Esther Zamora, Joaquin Arribas, Cristina Saura, Violeta Serra, Josep Tabernero, Bruce A. Littlefield, Josep Villanueva

Summary: Drug tolerant persister (DTP) cells enter a reversible slow-cycling state after treatment, with GDF15 identified as a key protein over-secreted and essential for their survival. Combining eribulin with an anti-GDF15 antibody may be effective in targeting and killing breast cancer DTP cells.

CANCERS (2022)

添加到收藏夹

Review Oncology

Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review

Farshid Dayyani, Teresa Macarulla, Andrew Johnson, Zev A. Wainberg

Summary: This review examines the treatment landscape for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who have undergone second- and later-line (>= 2L) treatment. A systematic literature review identified 60 publications, with 23 focusing on comparative trials. The analysis reveals that irinotecan-based regimens show the most promise for mPDAC treatment, but there is still a significant unmet need.

CANCER TREATMENT REVIEWS (2023)

添加到收藏夹

Article Oncology

Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation

Queralt Serra-Camprubi, Helena Verdaguer, Winona Oliveros, Nuria Lupion-Garcia, Alba Llop-Guevara, Cristina Molina, Maria Vila-Casadesus, Anthony Turpin, Cindy Neuzillet, Joan Frigola, Jessica Querol, Mariana Yanez-Bartolome, Florian Castet, Carles Fabregat-Franco, Carmen Escudero-Iriarte, Marta Escorihuela, Enrique J. Arenas, Cristina Bernado-Morales, Noemi Haro, Francis J. Giles, Oscar J. Pozo, Josep M. Miquel, Paolo G. Nuciforo, Ana Vivancos, Marta Mele, Violeta Serra, Joaquim Arribas, Josep Tabernero, Sandra Peiro, Teresa Macarulla, Tian Tian

Summary: It has been found that advanced cholangiocarcinoma patients with BRCA2 gene mutations are likely to benefit from PARP inhibitor therapy, while those with mutations in IDH1, ARID1A, or BAP1 will not. The patient-derived xenograft models provide new opportunities for evaluating drug response and prioritizing clinical trials.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹

Article Oncology

Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients

Margherita Rimini, Carles Fabregat-Franco, Mara Persano, Valentina Burgio, Francesca Bergamo, Monica Niger, Mario Scartozzi, Ilario Giovanni Rapposelli, Giuseppe Aprile, Francesca Ratti, Federica Pedica, Helena Verdaguer, Mario Rizzato, Federico Nichetti, Eleonora Lai, Alessandro Cappetta, Teresa Macarulla, Matteo Fassan, Filippo De Braud, Andrea Pretta, Francesca Simionato, Francesco De Cobelli, Luca Aldrighetti, Lorenzo Fornaro, Stefano Cascinu, Andrea Casadei-Gardini

Summary: This study investigated the prognostic impact of IDH1 mutations in patients with advanced iCCA after progression on first-line therapies. The presence of IDH1 mutations was associated with worse overall survival and worse objective response rate in second-line therapy. IDH1 mutations were confirmed as an independent negative prognostic factor.

TARGETED ONCOLOGY (2023)

添加到收藏夹

Review Oncology

Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment

Ignace Vergote, Teresa Macarulla, Fred R. Hirsch, Carsten Hagemann, David Scott Miller

Summary: Tumor Treating Fields (TTFields) are electric fields that inhibit cancer cell survival and tumor growth without harming healthy cells. TTFields therapy delivers the treatment to the tumor site noninvasively using skin arrays. Taxanes are commonly used chemotherapies that have side effects, and alternative treatments that enhance their efficacy without increasing side effects are needed.

CANCERS (2023)

添加到收藏夹

Article Oncology

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

James J. Harding, Jia Fan, Do-Youn Oh, Hye Jin Choi, Jin Won Kim, Heung-Moon Chang, Lequn Bao, Hui-Chuan Sun, Teresa Macarulla, Feng Xie, Jean-Phillippe Metges, Jie'er Ying, John Bridgewater, Myung-Ah Lee, Mohamedtaki A. Tejani, Emerson Y. Chen, Dong Uk Kim, Harpreet Wasan, Michel Ducreux, Yuanyuan Bao, Lisa Boyken, Jiafang Ma, Phillip Garfin, Shubham Pant

Summary: This study evaluated the efficacy and safety of the bispecific antibody zanidatamab targeting HER2 in treatment-refractory biliary tract cancer. The results showed meaningful clinical benefit and manageable safety profile of zanidatamab in patients with HER2-positive biliary tract cancer. These findings support the potential of zanidatamab as a future treatment option for HER2-positive biliary tract cancer.

LANCET ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform

Andrew H. Ko, Kyu-Pyo Kim, Jens T. Siveke, Charles D. Lopez, Jill Lacy, Eileen M. O'Reilly, Teresa Macarulla, Gulam A. Manji, Jeeyun Lee, Jaffer Ajani, Maria Alsina Maqueda, Sun-Young Rha, Janet Lau, Nedal Al-Sakaff, Simon Allen, Danny Lu, Colby S. Shemesh, Xinxin Gan, Edward Cha, Do-Youn Oh

Summary: This clinical trial evaluated the clinical activity of atezolizumab in combination with PEGPH20 in patients with pancreatic ductal adenocarcinoma or gastric cancer. The results showed limited clinical activity in patients with pancreatic ductal adenocarcinoma and none in patients with gastric cancer. The safety of the combination therapy was consistent with the known safety profiles of the individual agents.

ONCOLOGIST (2023)

添加到收藏夹

Article Genetics & Heredity

ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA

Ariana Huebner, James R. M. Black, Francesca Sarno, Roberto Pazo, Ignacio Juez, Laura Medina, Rocio Garcia-Carbonero, Carmen Guillen, Jaime Feliu, Carolina Alonso, Carlota Arenillas, Ana Belen Moreno-Cardenas, Helena Verdaguer, Teresa Macarulla, Manuel Hidalgo, Nicholas McGranahan, Rodrigo A. Toledo

Summary: In this study, the dynamic changes in somatic copy number alterations (SCNAs) in pancreatic adenocarcinoma were investigated using whole-exome sequencing and haplotype phasing. The results revealed a significant heterogeneity of SCNAs in the evolution of pancreatic cancer, including parallel focal and arm-level events affecting different parental alleles. This work highlights the importance of haplotype phasing in studying genomic variation and provides important implications for cancer research and clinical practice.

GENOME MEDICINE (2023)

添加到收藏夹

Review Oncology

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

M. Ducreux, G. K. Abou-Alfa, T. Bekaii-Saab, J. Berlin, A. Cervantes, T. de Baere, C. Eng, P. Galle, S. Gill, T. Gruenberger, K. Haustermans, A. Lamarca, P. Laurent-Puig, J. M. Llovet, F. Lordick, T. Macarulla, D. Mukherji, K. Muro, R. Obermannova, J. -M. O'Connor, E. M. O'Reilly, P. Osterlund, P. Philip, G. Prager, E. Ruiz-Garcia, B. Sangro, T. Seufferlein, J. Tabernero, C. Verslype, H. Wasan, E. Van Cutsem

Summary: This article summarises expert discussion on the management of patients with hepatocellular carcinoma (HCC), which took place during the 24th World Gastrointestinal Cancer Congress (WGICC) in Barcelona, July 2022. A multidisciplinary approach is essential for optimal diagnosis, staging, and planning of curative and therapeutic options for HCC, considering factors such as liver cirrhosis.

ESMO OPEN (2023)

添加到收藏夹

Review Oncology

Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications

Nadia Saoudi Gonzalez, Francesc Salva, Javier Ros, Iosune Baraibar, Marta Rodriguez-Castells, Ariadna Garcia, Adriana Alcaraz, Sharela Vega, Sergio Bueno, Josep Tabernero, Elena Elez

Summary: Metastatic colorectal cancer is a complex and life-threatening disease influenced by various factors. Tumor heterogeneity, caused by genetic and non-genetic factors, affects tumor development and therapy effectiveness. Computational analysis of next-generation sequencing and real-time monitoring of circulating tumor DNA are valuable tools in understanding tumor evolution and heterogeneity.

CANCERS (2023)

添加到收藏夹

Article Oncology

PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system

Kai Zimmer, Florian Kocher, Gerold Untergasser, Brigitte Kircher, Arno Amann, Yasmine Baca, Joanne Xiu, W. Micheal Korn, Martin D. D. Berger, Heinz-Josef Lenz, Alberto Puccini, Elisa Fontana, Anthony F. F. Shields, John L. L. Marshall, Michael Hall, Wafik S. S. El-Deiry, David Hsiehchen, Teresa Macarulla, Josep Tabernero, Renate Pichler, Moh'd Khushman, Upender Manne, Emil Lou, Dominik Wolf, Viktorija Sokolova, Simon Schnaiter, Alain G. G. Zeimet, Pat Gulhati, Gerlig Widmann, Andreas Seeber

Summary: Loss of function mutations in the PBRM1 gene are found in a fraction of biliary tract cancers (BTCs) and may be involved in chromatin remodeling and DNA damage repair. Through analyzing 1848 samples, it was found that PBRM1 mutations occur in 8.1% of BTCs and are more common in intrahepatic BTCs. Furthermore, PBRM1 mutations are associated with higher co-mutation rates in other chromatin remodeling and DNA damage repair genes. In vitro experiments showed that PBRM1-deficient BTC models are sensitive to PARP and ATR inhibitors. These findings provide a theoretical basis for future treatment of BTC patients with PBRM1 mutations.

NPJ PRECISION ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform

Andrew H. Ko, Kyu-Pyo Kim, Jens T. Siveke, Charles D. Lopez, Jill Lacy, Eileen M. O'Reilly, Teresa Macarulla, Gulam A. Manji, Jeeyun Lee, Jaffer Ajani, Maria Alsina Maqueda, Sun-Young Rha, Janet Lau, Nedal Al-Sakaff, Simon Allen, Danny Lu, Colby S. Shemesh, Xinxin Gan, Edward Cha, Do-Youn Oh

Summary: This study evaluated the efficacy and safety of the combination of atezolizumab and PEGylated recombinant human hyaluronidase in patients with advanced pancreatic ductal adenocarcinoma and gastric cancer. The results showed limited clinical activity of atezolizumab plus PEGPH20 in patients with pancreatic cancer and no significant effect in patients with gastric cancer. The safety profile of this combination was consistent with the known safety profiles of the individual agents.

ONCOLOGIST (2023)

添加到收藏夹

Article Oncology

A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas

Manuel Hidalgo, Rocio Garcia-Carbonero, Kian-Huat Lim, Wells A. Messersmith, Ignacio Garrido-Laguna, Erkut Borazanci, Andrew M. Lowy, Laura Medina Rodriguez, Daniel Laheru, Beatriz Salvador-Barbero, Marcos Malumbres, David J. Shields, Joseph E. Grossman, Xin Huang, Meggan Tammaro, Jean-Francois Martini, Yanke Yu, Kenneth Kern, Teresa Macarulla

Summary: This study evaluates the clinical efficacy and safety of palbociclib plus nab-paclitaxel in patients with advanced pancreatic ductal adenocarcinoma. The preclinical and clinical data suggest that this combination treatment has antitumor activity and tolerable toxicity, but does not meet the prespecified efficacy threshold.

CANCER RESEARCH COMMUNICATIONS (2022)

添加到收藏夹

Article Oncology

Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer

Ruth Vera, Carolina Ibarrola-de-Andres, Jorge Adeva, Judith Perez-Rojas, Pilar Garcia-Alfonso, Yolanda Rodriguez-Gil, Teresa Macarulla, Teresa Serrano-Pinol, Rebeca Mondejar, Beatriz Madrigal-Rubiales

Summary: Pancreatic cancer and biliary tract cancer have poor prognoses. New diagnostic techniques have identified the main genetic alterations involved in tumor development. Certain biomarkers have shown predictive ability in treatment response. Recommendations are proposed to optimize the determination of these biomarkers to standardize the diagnosis and treatment of these tumors.

CLINICAL & TRANSLATIONAL ONCOLOGY (2022)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.